ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 12c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Nvidia to commit $3 bln to Meta share offering as part of bigger AI partnership
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Boeing free cash flow beats estimates despite production challenges
Tweet
Share
E-mailGet Alerts SPRY Hot Sheet
Join SI Premium – FREE
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q1 EPS of ($0.61), $0.12 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $22.67 million.
For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning shares rise 3% in premarket trade after Q3 EPS, revenue beat estimates
- Camden National (CAC) Reports In-Line Q3 EPS
- Galaxy Digital (GLXY) PT Lowered to $35 at BTIG
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
